Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) just unveiled an update.
Shanghai MicroPort MedBot announced that cumulative orders for its core robotic surgery products have surpassed 230 units, with its flagship Toumai laparoscopic surgical robot accounting for more than 160 commercial orders globally and ranking among the top two worldwide by 2025 order volume. The company has now completed over 150 commercial installations across its product range, including more than 100 Toumai units that meet revenue recognition criteria under HKFRS, making Toumai the first domestic laparoscopic surgical robot to reach the 100-unit commercial installation milestone. Management highlighted that this scale demonstrates system reliability, clinical stability and strengthened capabilities in quality, production and delivery, while domestically Toumai has gained strong traction in leading hospitals, with over 90% of installations in Grade‑IIIA facilities and 23% in China’s top 100 hospitals, helping diffuse advanced robotic surgery from top-tier centers to regional and primary hospitals. Internationally, Toumai’s footprint now spans over 40 countries and regions, achieving multi-unit sales and multi-hospital deployments in 15 markets and underpinning a growing global robotic surgery ecosystem that integrates top experts, regional medical centers and primary hospitals, reinforcing the company’s competitive positioning in the rapidly expanding medical robotics industry.
The most recent analyst rating on (HK:2252) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a China-based medical robotics company specializing in surgical robot systems for laparoscopic, orthopedic and vascular interventional procedures. The group targets multi-tiered healthcare systems in China and overseas, positioning its flagship Toumai laparoscopic surgical robot in top public and high-end private hospitals, and expanding its presence across more than 40 countries and regions worldwide.
Average Trading Volume: 3,511,826
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.93B
For an in-depth examination of 2252 stock, go to TipRanks’ Overview page.